GC
TMBR

Guggenheim Capital’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Guggenheim Capital’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$7K – 2675
2018
Q1 		$7K Hold
2
– – ﹤0.01% 2773
2017
Q4 		$3K Hold
2
– – ﹤0.01% 2706
2017
Q3 		$9K Hold
2
– – ﹤0.01% 2783
2017
Q2 		$11K Hold
2
– – ﹤0.01% 2806
2017
Q1 		$11K Buy
+2
New +$13.8K ﹤0.01% 2813

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Guggenheim Capital's TMBR Position: Q2 2018 in Review

Guggenheim Capital sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q2 2018, closing a stake of 2 shares — an estimated $7K sold.

Guggenheim Capital first reported a position in TMBR in Q1 2017 and held it in 5 quarters. The position peaked at $11K in Q2 2017. 19 funds tracked by Wall St. Rank hold TMBR as of Q2 2018.

  • Guggenheim Capital reported no remaining Timber Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 2 Timber Pharmaceuticals, Inc. shares in Q2 2018, an estimated $7K.
  • Guggenheim Capital first reported a position in Timber Pharmaceuticals, Inc. in Q1 2017 and held it in 5 quarters.
  • Guggenheim Capital's Timber Pharmaceuticals, Inc. position peaked at $11K in Q2 2017.
  • 19 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.